


Figure 1





Figure 2

A


CD4+ CD45RA+ cells
Median Fluorescence Intensity
1,200
900
600
300
0
CD4+ 1.3
Kd = 24 nM
CD4+ 4.5
Kd = 6.9 nM
10-3
10-2
10-1
100
101
102
[Ab] (nM)

B



CD8+ CD45RA+ cells
Median Fluorescence Intensity
1,200
900
600
300
0
CD8+ 1.3
Kd = 27 nM
CD8+ 4.5
Kd = 6.9 nM
10-3
10-2
10-1
100
101
102
[Ab] (nM)

Figure 3




Figure 4




Figure 5




Figure 6



CD16+ NK
CD3+ T
Donor1
Donor2
Donor3
Donor4
Donor5
Donor6
Donor7
Donor8
CD16
CD45RO
CD27

Figure 7




Figure 8




Figure 9



Human
Monocytes
CD8+CD3+
CD8-CD3+
CD16+
CD3-CD8-
18C3
2D3
Anti-PD-1 Antibody
1.3
4.5
7.8
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
AA
AB
AC
AD

Figure 10



Cynomolgus Monkey
Monocytes
CD8+CD3+
CD8-CD3+
CD16+
CD3-CD8-
18C3
2D3
Anti-PD-1 Antibody
1.3
4.5
7.8
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
AA
AB
AC
AD

Figure 11



HLA-ABC
Counts
0 10² 10³ 10⁴ 10⁵
Comp-FITC-A
(A)
B7-H1
Counts
0 10² 10³ 10⁴ 10⁵
Comp-PE-A
(B)
HLA-DR
Counts
0 10² 10³ 10⁴ 10⁵
Comp-PerCP-Cy5-5-A
(C)
CD40
Counts
0 10² 10³ 10⁴ 10⁵
Comp-PE-Cy7-A
(D)
CD86
Counts
0 10² 10³ 10⁴ 10⁵
Comp-APC-A
(E)
Isotype Control
Immature DC
TNFa+PGE2 Day 1
TNFa+PGE2 Day 2

Figure 12




Figure 12 (continued)



Percentage of divided cell (CFSE low)
50.00
40.00
30.00
20.00
10.00
0.00
Ctl Ig
H7CR1.3
H7CR4.5
H7CR7.8
T cell only
Day6
Day7
Day10

Figure 13



25 fold
IFN-γ
A
pg/ml
1800
1600
1400
1200
1000
800
600
400
200
0
Ctl Ig
H7CR1.3
H7CR4.5
H7CR7.8
T cell only
IL-5
B
pg/ml
30
25
20
15
10
5
0
Ctl Ig
H7CR1.3
H7CR4.5
H7CR7.8
T cell only

Figure 14




Figure 14 (continued)




Figure 14 (continued)




Figure 14 (continued)




Figure 14 (continued)




Figure 14 (continued)



A
Ctl Ig
Q1
0.016%
Q2
0.007%
*0.15%
Q4
6.39%
Q3
93.6%
10^5
10^4
10^3
10^2
0
0 10^2 10^3 10^4 10^5
Comp-FITC::CFSE
Comp-PerCP-Cy5-5-A::IFNg
IFN-γ
CFSE
B
H7CR1.3
Q1
0.107%
Q2
0.007%
*0.96%
Q4
11.2%
Q3
88.7%
10^5
10^4
10^3
10^2
0
0 10^2 10^3 10^4 10^5
Comp-FITC::CFSE
Comp-PerCP-Cy5-5-A::IFNg
IFN-γ
CFSE

Figure 15





Figure 16A



Panel A Panel B

Figure 16B




Figure 17A




Figure 17B




Figure 18A




Figure 18B




FIG. 19A

FIG. 19B

FIG. 19C

FIG. 19D





FIG. 20A

FIG. 20B

FIG. 20C

FIG. 2


Cd8+
Control
Anti-H7CR
Cd107a
IFN-γ
FL2-H: CD107a
FL4-H: CD3
FL1-H: IFN-gamma
FL4-H
7.98
92
18.1
81.9
15.6
84.4
53.8
45.5
0.34
0.34
0
FIG. 20E
FIG. 20F
FIG. 20G
FIG. 2




FIG. 21A

FIG. 21B

FIG. 22



Control
CHO-H7CR-GFP
LC1-1
LC1-2
LC1-3
LC2-1
LC2-2
LC2-3
H7CR4.5
HC1-1
HC1-2
HC1-3
HC2-1
HC2-2
HC2-3
GFP

FIG. 23